The prevalence and burden of heavy menstrual bleeding, and market access barriers of medical interventions with a focus on low- and middle-income countries: a scoping review

中低收入国家月经过多的患病率和负担,以及医疗干预措施的市场准入障碍:一项范围界定综述

阅读:2

Abstract

BACKGROUND: Heavy menstrual bleeding (HMB) is defined as excessive menstrual blood loss that negatively affects physical, emotional, social, and quality of life (QoL) of women at reproductive age. The aim of this systematic scoping review was to map and summarize the available evidence on the prevalence, burden, treatment, and barriers to accessing treatment for HMB in low- and middle-income countries (LMICs). METHODS: We conducted a review of published data in nine databases and included studies published from 1 January 2000 to 28 October 2024. Covidence was used for screening and data extraction. RESULTS: We identified 376 eligible studies conducted in 46 countries. Most of the studies (300, 80%) reported on the treatment of HMB (including 9 studies on treatment and burden), 55 reported on prevalence, 19 reported on burden (including 12 studies on burden and prevalence) and two studies reported on barriers to providing treatment. A total of 55 systematic reviews were included. Prevalence of HMB ranged from 5% to 58%, using a variety of diagnostic and reporting methods. Burdens of HMB included impaired QoL, mental health issues, economic burdens, and health concerns such as anemia. The use of a hormonal intrauterine device was the most commonly reported treatment for HMB (n = 120), followed by progestin (n = 41), combined oral contraceptives (n = 36), gonadotrophin-releasing hormone (n = 31), and tranexamic acid (n = 23). Thirty studies focused on herbal treatment. Lack of knowledge and misunderstanding of treatment options for HMB were mentioned as barriers for HMB treatment. CONCLUSION: The prevalence of HMB and the variety of treatment options available indicate that HMB is a condition that should not be underestimated and has a large impact on women’s health and well-being. There is a need for reliable, good-quality studies on the prevalence, burden, and treatment access barriers of HMB, especially in LMICs where HMB more often leads to iron deficiency anaemia. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12905-025-04157-5.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。